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at the end ot treatmenł. We have noted also 38
patients (15%) ot 254 patients, with deacresing
hemoglobin level during treatment higher than
1 gid!.
Results: No impact on outcome ot treatment
was observed in the group ot patients with low
level ot Hgb betore irradiation. Inrease ot
locoregional failure ot postoperative radiotherapy
was noted in group of patients with Hgb level at
the end of irradiation below 13 g/dl (p = 0,004)
and also in group ot patients with decreasing of
Hgb level during treatment (p = 0,038).
Conclusions: Low Hgb levels at the end of
postoperative irradiation and decreasing during
irradiation were associated with a statistically
signiticant an increase in locoregional failure ot
patients with advanced carcinoma of larynx.
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surrounding tissues, excellent cosmetic eftect
,economical procedure.
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ALLOGENEIC BONE MARROW
TRANSPLANTATlON IN CHILOREN
WITH ACUTE LYMPHOBLASTIC
LEUKEMIA IN FIRST AND SECOND
COMPLETE REMISSlON CONDI-
TIONED WITH FRACTIONATED
TOTAL BODY IRRADIATION AND
ETOPOSIDE OR CYCLOPHOSPHA-
MIDE
J. Wachowiak1, J. Malicki2, o. Boruczkowski1,
G. Słryczyńska 2, G. Kosicka2 , M. Leda1,
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STEREOTACTIC
BREAST BIOPSY
RESULTS
MAMMOTOME
ANALlSIS OF
HSCT Unit, Institute ot Pediatrics1 & Great
Poland Cancer Center2 , Poznań, Poland.
P. Murawa, T. Fedorowicz, R. Kobylarek,
W. Nowakowski, J. Wasiewicz
I Oddział Chirurgii Wielkopolskiego Centrum
Onkologii, Poznań.
The purpose ot work is to assess stereotactic
mammotome biopsy technology in diagnostics
ot nonpalpable breast lesions. In the period tram
April to December 2000 mammotome biopsy
procedure was performed on395 female patients
at the I Oncological Surgery department the
Greatpoland CancerCenter in Poznań .In all
patients, diagnosed lesions were non-palpable
and categorisedas BI-RADS III, IV, V. Patients
were aged between 16 and 78 (average 52.6
years). They divided into three groups
depending on radiological characteristics ot the
examined lesions - separate analyses were
carried out tor patients with microcalcifications
suspicious tumores and radial scar. Diagnostic
examination was performed on an ambulatory
basis. Procedurewas carried out on a Fischer
mammotome table using the Mammotome
Biopsy System. The Cancers were detected in
17 % cases .AII patients with diagnosed cancer
underwent further surgical procedure. In 83 %
patients in whom begin lesions were tound
mammography screening was recommended at
6 month intervals. The Stereotactic
Mammotome Breast Biopsy System is a
sensitive, minimally invasive diagnostic
technology characterised by: very high
diagnostic precision, minimai traumatisation of
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Patients and mełhods: From 1993 to 2001
thirty two children underwent bone marraw
transplantation (BMT) tor ALL (12 in I CR and 20
in II CR after early BM or BM/organ relapse).
Except 2 syngeneic all other were HLA-identical
siblings transplants. Ali patients (pts) were
conditioned with FTBI 2 x 1,5 Gy for 4 days
(total dose 12 Gy) with lung shielding (9 Gy) and
CY 60 mg/kg i. v for 2 days (total dose 120
mg/kg) (n=1 in I CR and n = 11 in II CR) or VP
60 mg/kg i. v (n = 11 in I CR and n = 9 in II CR).
Pts in I CR have been given 1,1-4,9x1 OB
MNC/kg (med. 2,7x10B/kg), while pts in II CR
1,9-4,Ox1 OB MNC/kg (med. 2,7x1 OB/kg). For
GvHD prevention CsA 3 mg/kg/d i.v was
administered alone in 22 pts (n = 9 in I CR and n
= 13 in II CR) or in combination with "short" MTX
+/- PRED in 8 pts (n =3 in I CR and n =5 in II
CR). Two pts transplanted with syngeneic BM
received no GvHD prevention. Regimen related
toxicity (RRT) was graded according to the
system developed by Bearman et al. (1988).
Results: Only mild or moderate expression ot
RRT was observed (Gl toxicity 10 - 80%, 110 -
4%; stomatitis 10 - 40%, 110 - 20%; hepatic
toxicity 10 - 28%; renal, bladder and cardiac
toxicity 10 - 4%) and no transplant related deaths
occured (TRM = 0%). Among 12 pts
transplanted in I CR only one child relapsed 4
months trom BMT, while remaining 11 pts are
alive in CCR with a median follow-up of
33months (range 6 to 66 months) and 92%
prabability of 5-year EFS. Of 20 children
transplanted in II CR 6 relapsed 1-14 months
tram BMT (median 6,5 months). Fourteen ot
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them remain in CCR with a median tollow-up
19,5 months (range 1 to 96 months) and 66%
probability ot 8-year EFS.
Conclusions:
1. In ehildren with ALL the FTBI-12Gy-
eontaining regimen is well tolerated
without the lite-threatening toxie
eomplieations.
2. FTBI-12Gy-eontaining regimen demon-
strates very good antileukemie efficacy tor
HR-ALL in I CR, but only Iimited tor ALL in
liCA.
3. 3. In context ot good tolerance ot FTBI in
atotal dose ot 12 Gy and its Iimited
antileukemie efficacy in ehildren with ALL
in II CR the escalation ot FTBI total dose
trom 12 Gy to 13,2 Gy appears to be
justitied in those children. Suppońed by
grant KBN 4 P05E 108 18.
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COMBINED CHEMOTHERAPY AND
RADlATlON IN LOCALLy ADVANCED
NSCLC
J. Jassem
Dept. ot Oncology and Radiotherapy, Medical
University ot Gdansk, Poland
In loeally advaneed inoperable NSCLC
radiotherapy has traditionally been considered
the mainstay of treatmenł. Unfortunately, in most
instances this method does not allow for
eradication ot bulky tumor in the thorax and does
not prevent uncontrolled systemie disease. In
consequence the prognosis of these patients is
dismai and has remained essentially unchanged
within the last decades. The five-year survival
rates after irradiation varies between 3 and 10%.
During the last decades several approaches have
been tested to improve this outcome. Of those,
particular attention has toeused on combining
chemotherapy and radiation. Two most trequently
used strategies have included induetion
ehemotherapy folIowed by radiation, or
eoncurrent ehemoradiation. The results of a few
phase III triais comparing radiation alone with
radiation supplemented by chemotherapy have
demonstrated modest yet signifieant survival
benefit from the combined approach. Two recent
studies suggested that coneomitant
ehemoradiation might be more effeetive than
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ehemotherapy preceding radiation. The gain
from the eoneurrent use ot both modalities
should however be weighted against inereased
toxicity. Further studies built upon recent
positive results should toeus on identifying
means of optimal interaetions between the two
modalities. This research should define the most
effeetive types and doses of antieancer agents
as well as the optimal teatures ot radiotherapy.
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ADJUVANT TREATMENT TO
SURGERY: IS IT STILL A PLACE FOR
RADIO-OR CHEMOTHERAPY?
P. van Houtte
Institut Jules Bordet, Brussels, Belgium
The two metaanalysis conducted by the
Cambridge group has cent the seene for
adjuvant treatment as well as the pattem of
failure analysis after surgery. In the pattem of
failure analysis peńormed after a complete
resection, local failure is a race event for
pathologieal stage 1 and II disease (less than 10
%). In opposite, for stage III, local tailure
remains an issue due to the wide range ot tumor
extent, from reseetable disease to unresectable
tumor. In eontrast, distant metastasis is a
common problem with figures ranging from 20 to
50%. A last issue is eertainly the problem ot
second cancer induced by a long history of
tobaeeo smoking rising the question of
chemoprevention.
To prevent distant metastasis, a systemie
treatment is the logical answer. The
metaanalysis suggested a slight nonsignificant
benefit for a sequential Cisplatine based
chemotherapy. The recent American trial of
Keller et al comparing postoperative
radiotherapy to a eombined ehemo-radiotherapy
approaeh did not showed any differenee for
stage III disease: the only important prognostic
tactor was the type ot mediastinal exploration:
sampling vs. radical disseetion. Several triais
are on going worldwide: Anita, ALPI, and lALT...
The main characteristics of those triais are to
include a cisplatine based chemotherapy
program and a large number ot patients. This
implies necessary a low efficacy; a smali
differenee is expeeted. Furthermore, the already
published triais showed a low eompliance to
chemotherapy.
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